Chardan cuts price target on Editas Medicine from $43 to $35, retains buy rating

MT News Reports 2022

All news about EDITAS MEDICINE, INC.

Analyst Recommendations on EDITAS MEDICINE, INC.

Sale 2022 17.1 M

Net income 2022 -222M

Net cash 2022 361 M

P/E ratio 2022 -3.43x
Yield 2022
Capitalization 741 M
741 M
EV / Sale 2022 22.2x
EV / Sales 2023 24.5x
Number of employees 264
Free floating 99.5%


Duration :

Period of time :

Editas Medicine, Inc.  Technical Analysis Table |  Market Screener

Trends in Technical Analysis EDITAS MEDICINE, INC.

Short-term Intermediate Long-term
trends Neutral Neutral bearish

Evolution income statement

To sell

To buy

Average consensus DELAY
Number of analysts 18
Last closing price $11.01
Average target price $18.47
Spread / average target 67.7%

Leave a Comment